DSP Healthcare Fund - Regular Plan - Growth
DSP Healthcare Fund will help you grow your money over the long term by targeting companies within the healthcare and pharmaceutical industries.
Primary Goal
Earn capital appreciation through investing in a majority of equities that have connections to healthcare.
In What It Investigates
- More than 80% in Indian healthcare and pharmaceutical companies
- Overseas healthcare stocks up to 25%
Additional Allocations
- Debt or money-market instruments (up to 20% to provide stability)
- REITs/InvITs (up to 10% to better diversify)
Nav and CAGR Return
Fund Overview
Holdings & Sector Allocations
The fund's strategy is reflected in its distribution of assets across top companies and sectors.
Top 5 Holdings (% of Net Assets)
| Company | % of Net Assets |
|---|---|
| Suven Pharmaceuticals Ltd. | 10% |
| Sun Pharmaceutical Industries Ltd. | 10% |
| Cipla Ltd. | 10% |
| IPCA Laboratories Ltd. | 8% |
| Globus Medical Inc. | 6% |
Top 3 Sectors (% of Net Assets)
| Sector | % of Net Assets |
|---|---|
| Healthcare & Consumer Services | 97% |
| Financial Services | 2% |
| Others | 0.5% |
Performance Metrics
28.15%
Mar 2020 – Mar 2025
15.92%
Volatility Measure
0.86
vs. Benchmark
0.86
Risk-Adjusted Return
SIP Performance (Growth Option)
Systematic Investment Plan (SIP) returns for both Regular and Direct plans, showing the growth of periodic investments.
Regular Plan
| Period | Invested (₹'000) | Market Value (₹'000) | SIP Returns (%) |
|---|---|---|---|
| 1 Year | 24 | 24 | –1.12% |
| 3 Years | 72 | 100 | 22.27% |
| 5 Years | 120 | 194 | 19.30% |
| Since Inception | 156 | 323 | 22.16% |
Direct Plan
| Period | Invested (₹'000) | Market Value (₹'000) | SIP Returns (%) |
|---|---|---|---|
| 1 Year | 24 | 24 | 0.24% |
| 3 Years | 72 | 102 | 23.97% |
| 5 Years | 120 | 202 | 20.94% |
| Since Inception | 156 | 342 | 23.95% |
Lumpsum Performance (₹10,000 at Inception)
Growth of a one-time investment of ₹10,000 from Nov 30, 2018, to Apr 30, 2025.
| Plan | Fund Value | BSE Healthcare TRI | Nifty 50 TRI |
|---|---|---|---|
| Regular Growth | ₹ 37,120 | ₹ 30,708 | ₹ 24,088 |
| Direct Growth | ₹ 40,851 | ₹ 30,708 | ₹ 24,088 |
IDCW History (per Unit)
| Record Date | IDCW per Unit (₹) |
|---|---|
| 25 Mar 2021 | 1.84 |
| 03 Mar 2022 | 1.80 |
| 01 Mar 2023 | 1.40 |
| 29 Feb 2024 | 2.00 |
| 25 Feb 2025 | 2.10 |
Key Insights
Unified Sector Focus with Flexibility
The fund primarily invests 80-100% of its assets in healthcare and pharmaceutical equities, ensuring a strong thematic focus. It maintains flexibility by allowing up to 20% investment in non-healthcare stocks or debt instruments for diversification and risk management.
Tactical Diversification Levers
It can allocate up to 25% to foreign healthcare equities for global exposure and up to 10% in REITs/InvITs, adding a real estate revenue dimension to the portfolio.
Long-Term Outperformance
While short-term performance (1-3 years) has occasionally lagged its benchmark, the fund has shown strong outperformance over 5 years and since its inception, highlighting a successful long-term strategy. The 5-year return is 28.15% vs the benchmark's 28.56% (a close race), but since inception, it's a clear lead at 23.14% vs 19.01%.
Lower Expense in Direct Plan
The Direct Plan's Total Expense Ratio (TER) is significantly lower (0.60%) compared to the Regular Plan (1.94%), making it a more cost-effective choice for direct investors.
Low Portfolio Turnover
A low portfolio turnover ratio of 0.1926 indicates a buy-and-hold strategy. This approach minimizes trading costs and potential tax implications, aligning with long-term wealth creation.